Antiparkinson Drugs Flashcards
cardinal features of parkinsons
resting tremor, muscular rigidity, bradykinesia, gait impairment
principal metabolite of dopamine
HVA - homovanillic acid
what do the D1 and D2 receptors do
- D1: activated adenylyl cyclase
- D2: inhibits adenylyl cyclase, opens K+ channels, suppresses Ca2+ currents
classification of drugs used to treat parkinsons
AAIDD
Amantadine
Antimuscarinics
Inhibitors of Dopamine Metabolism: COMT and MAO
Dopamine Precursors
Dopamine Receptor Agonists: Ergot and Non-ergot dopamine agonists
what is the dopamine precursor drug
Levodopa
mechanism of levodopa
transported into the brain by facilitative L transport system –> converted to dopamine in the brain using DOPA decarboxylase
what drug is given with levodopa and why
Carbidopa - Dopa decarboxylase inhibitor
- it does not cross into the brain but works in the periphery by preventing conversion to dopamine in the periphery so that most of the L-DOPA can cause into the brain
- also conversion to dopamine in periphery –> nausea, vomiting, cardiac arrhythmias, hypotension
what is Sinemet
preparation containing carbidopa and L-DOPA in fixed preparation
what is levodopa’s metabolite
homovanillic acid (HVA) dihydroxyphenylacetic acid (DOPAC)
what happens with long term use of levodopa
it is only effective for 3-5 years then responsiveness becomes lost completely
AE of levodopa
GI effects (dopamine agonists cause nausea and vomiting) CNS effects (Visual and auditory hallucinations and dyskinesia) CVS effects (dopamine stimulates heart -- tachycardia)
what is the on-off phenomenon seen with levodopa
-off periods of marked akinesia alternate over on periods of improved mobility but often marked dyskinesia
contraindications of levodopa
HAV PAMP
- Hypertensive crisis with Phenelzine or Tranylcypromine (MAOI)
- Angle closure glaucoma
- Vitamin B6 (co factor for L-dopa decarboxylase)
- Psychotic patients esp if on Antipsychotics
- Arrhythmias in cardiac patients
- Melanoma
- Peptic ulcers
what are the dopamine receptor agonists
Ergot derivatives: Bromocriptine
Non ergot derivatives: PARR Pramipexole Apomorphine Ropinirole Rotigotine
mechanism of bromocriptine and what is it used to treat
D2 agonist
Parkinsons
Hyperprolactinemia
mechanisms of the non ergot derivatives dopamine agonist
Pramipexole: preferential affinity for D3 receptors
Apomorphine: dopamine agonist
Ropinorole: purely D2 receptor agonist
Rotigotine: transdermal formulation that is dopamine agonist
AE of the nonergot dopamine agonists (minus apomorphine)
GI effects (nausea and vomiting) CVS effects Dyskinesia Mental disturbances: hallucination etc Somnolence
harder ones to reason out:
Pulmonary Infiltrates
Pleural and Retroperitoneal Fibrosis
Erythromelalgia
long term complication of ergot derivatives dopamine agonist
painless digital vasospasm
when is apomorphine usually used
in off periods of akinesia in patients on dopaminergic therapy
since apomorphine is highly emetogenic, what pre treatment is usually used
Trimethobenzamide
Domperidone
contraindication of apomorphine
5-HT3 antagonist -> profound hypotension and loss of consciousness
AE of apomorphine
QT prolongation
what are the inhibitors of dopamine metabolism
MAO inhibitors: Selegiline and Rasagiline
COMT inhibitors: Tolcapone and Entacapone
what are the MAOIs used for in treatment of parkinson
- Selegeline: selectively inhibits MAO-B so prevents breakdown of dopamine and enhances effect of levodopa (little chance for hypertensive crisis)
- Rasagiline: prolongs effects of levodopa-carbidopa in parkinson patients